Nuclera Secures US$75m to Advance Protein Discovery System
Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.
Nuclera, a biotech company based in Cambridge, UK, has raised US$75m in a Series C funding round led by Elevage Medical Technologies, backed by Patient Square Capital. Other participants include British Patient Capital and Cambridge Innovation Capital. This latest funding builds on the success of a previous financing round in 2022, during which Nuclera raised US$42.5m, demonstrating the company’s ability to attract significant investment and solidifying its position in the biotech space. The new funds will accelerate the commercialization of Nuclera’s eProtein Discovery™ system in the US and Europe.
“This funding will accelerate our mission to provide ready-to-use benchtop protein screening tools, empowering protein scientists around the world,” said CEO and co-founder Dr. Michael Chen (photo). Founded in 2013, Nuclera initially gained recognition for its innovative desktop DNA and protein printing technology. The company’s latest breakthrough, the eProtein Discovery system, continues to transform protein research by enabling labs to express and purify proteins in under 48 hours—significantly faster than traditional methods that can take months or even years.
Nuclera’s technology is particularly timely in light of the 2024 Nobel Prize in Chemistry, which highlighted the critical role of artificial intelligence in accelerating protein design and development. As AI-driven protein research advances, tools like Nuclera’s eProtein Discovery system, capable of producing high-quality proteins at speed and scale, are becoming essential for biotech and pharmaceutical innovation.
Already in use at leading research institutions and biotech companies, the eProtein Discovery system is designed for both cell-free and cell-based protein production, providing scientists a versatile solution to advance protein research globally.
